Papillomavirus

PDS Biotech Announces Release of Abstract for PDS0101 in NCI-Led Phase 2 Clinical Study for Oral Presentation at 2021 ASCO Meeting

Retrieved on: 
Thursday, May 20, 2021
Cancer treatments, Clinical medicine, Cancer, Cancer immunotherapy, Papillomavirus, Antineoplastic drugs, Virotherapy, Otorhinolaryngology, Pembrolizumab, Head and neck cancer, Merck & Co., Human papillomavirus infection

The abstract summarizing interim data from the National Cancer Institute (NCI)-led phase 2 trial has been accepted for oral presentation at the 2021 ASCO Annual Meeting taking place June 4-8.

Key Points: 
  • The abstract summarizing interim data from the National Cancer Institute (NCI)-led phase 2 trial has been accepted for oral presentation at the 2021 ASCO Annual Meeting taking place June 4-8.
  • Julius Strauss, Staff Clinician, LTIB, is serving as the Principal Investigator of this phase 2 clinical trial in advanced HPV-associated cancers.
  • The company\xe2\x80\x99s lead investigational cancer immunotherapy product PDS0101 is currently in Phase 2 clinical studies in HPV-associated cancers.
  • In partnership with Merck and Co., PDS Biotech is evaluating a combination of PDS0101 and KEYTRUDA\xc2\xae in a Phase 2 study in first-line treatment of recurrent or metastatic head and neck cancer.

HOOKIPA to present Phase 1 safety, tolerability and preliminary anti-tumor activity data on HB-201 and HB-202 for the treatment of advanced HPV16+ cancers at ASCO

Retrieved on: 
Thursday, May 20, 2021
Infectious causes of cancer, Papillomavirus, Carcinogenesis, Carcinogens, Human papillomavirus infection, Oncology, Papillomaviridae, Medical specialties, Clinical medicine, Biology

HB-201 and HB-202, novel arenaviral therapeutics and HOOKIPA\xe2\x80\x99s lead oncology candidates, are being evaluated in an ongoing, first-in-human Phase 1/2 clinical trial (NCT04180215) for the treatment of advanced Human Papillomavirus 16-positive (HPV16+) cancers.

Key Points: 
  • HB-201 and HB-202, novel arenaviral therapeutics and HOOKIPA\xe2\x80\x99s lead oncology candidates, are being evaluated in an ongoing, first-in-human Phase 1/2 clinical trial (NCT04180215) for the treatment of advanced Human Papillomavirus 16-positive (HPV16+) cancers.
  • Joern Aldag, Chief Executive Officer, and Igor Matushansky, Chief Medical Officer, will provide an overview of the ASCO oral data and future plans for HOOKIPA\xe2\x80\x99s oncology program.
  • The primary endpoint of the Phase 1 is a recommended Phase 2 dose based on safety and tolerability.
  • It is possible that the information we post on social media could be deemed to be material information.

Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clinical Trial of RTX-321 for HPV 16-Positive Cancers at the 2021 American Society of Clinical Oncology Annual Meeting

Retrieved on: 
Wednesday, May 19, 2021
Papillomavirus, Infectious causes of cancer, Carcinogenesis, Carcinogens, Human papillomavirus infection, Forward-looking statement, Medical specialties, Clinical medicine, Articles

A critical need remains for better treatment options for advanced HPV 16-associated cancers.

Key Points: 
  • A critical need remains for better treatment options for advanced HPV 16-associated cancers.
  • The purpose of the trial is to determine the safety and tolerability, recommended Phase 2 dose and pharmacology, and antitumor activity of RTX-321.
  • We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.
  • We explicitly disclaim any obligation to update any forward-looking statements.\n'

SQZ Biotechnologies to Present First Clinical Data at the American Society of Clinical Oncology Annual Meeting from Ongoing Phase 1 Study in Patients with Advanced or Metastatic HPV+ Tumors

Retrieved on: 
Wednesday, May 19, 2021
Oncology, Health, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Cancer, Clinical medicine, Medicine, Papillomavirus, Infectious causes of cancer, Carcinogenesis, Carcinogens, Human papillomavirus infection, Checkpoint inhibitor, Cancer immunotherapy, Human Papillomavirus Positive Cancers, SQZ Biotechnologies, HUMAN PAPILLOMAVIRUS POSITIVE CANCERS, SQZ BIOTECHNOLOGIES

In the next stage of the trial, it is planned to combine SQZ-PBMC-HPV-101 with immune checkpoint inhibitors.

Key Points: 
  • In the next stage of the trial, it is planned to combine SQZ-PBMC-HPV-101 with immune checkpoint inhibitors.
  • The study\xe2\x80\x99s primary outcome measures in the monotherapy stage of the trial are safety, tolerability, and the definition of the recommended phase 2 dose.
  • The investigational candidate, which targets E6 and E7 oncoproteins, is being studied as a monotherapy and in combination with immuno-oncology agents.
  • The planned safety combination phase of the study will include SQZ-PBMC-HPV-101 and checkpoint inhibitors that have previously received regulatory approval.

BD Announces Industry-First CE Marked Assay for HPV Screening from At-Home Self-Collected Vaginal Samples

Retrieved on: 
Thursday, May 13, 2021
Cancer, Infectious causes of cancer, Clinical medicine, Gynaecological cancer, Medicine, Papillomavirus, Cancer screening, Cervical screening, Human papillomavirus infection, Cervical cancer, Screening

"\nAt-home collection will help address the urgent public health challenge of reaching women who do not attend routine cervical cancer screening.

Key Points: 
  • "\nAt-home collection will help address the urgent public health challenge of reaching women who do not attend routine cervical cancer screening.
  • "HPV self-sampling makes screening accessible to women who don\'t participate in screening or have limited access to screening.
  • The BD OnclarityHPV Assay has FDA approval for clinical use in cytology-based screening with ASC-US triage, in co-testing paradigm, and in primary HPV screening.
  • For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo .\n'

Rubius Therapeutics Announces Publication of RTX-321 Preclinical Data in Nature Communications

Retrieved on: 
Wednesday, May 12, 2021
Papillomavirus, Infectious causes of cancer, Carcinogenesis, Carcinogens, Human papillomavirus infection, Medical specialties, Clinical medicine, Health

Our publication describes an elegant mechanism of action for RTX-321, combining antigen-specific responses with the addition of broad immune stimulation,\xe2\x80\x9d said Laurence Turka, M.D., chief scientific officer of Rubius Therapeutics.

Key Points: 
  • Our publication describes an elegant mechanism of action for RTX-321, combining antigen-specific responses with the addition of broad immune stimulation,\xe2\x80\x9d said Laurence Turka, M.D., chief scientific officer of Rubius Therapeutics.
  • A critical need remains for better treatment options for advanced HPV 16-associated cancers.
  • The purpose of the trial is to determine the safety and tolerability, recommended Phase 2 dose and pharmacology, and antitumor activity of RTX-321.
  • We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.

Cue Biopharma Reports Confirmed Partial Response (PR) in Ongoing Phase 1 Monotherapy Study of CUE-101 in Late Stage Second Line and Beyond Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer

Retrieved on: 
Monday, May 10, 2021
Medical specialties, Branches of biology, Otorhinolaryngology, Infectious causes of cancer, Papillomavirus, Head and neck cancer, Clinical medicine, Human papillomavirus infection, Natural killer cell

This provides evidence that CUE-101 is an active agent with promising potential for HPV+ HNSCC patients.

Key Points: 
  • This provides evidence that CUE-101 is an active agent with promising potential for HPV+ HNSCC patients.
  • This is bolstered by the supporting pharmacodynamic data in which we have observed activation of disease-specific T cells and NK cells in the blood of our treated patients.
  • We anticipate a number of important milestones throughout this year with the potential of further data to inform CUE-101\xe2\x80\x99s clinical application.
  • Based on translational data from the trial, a maximum tolerated dose (MTD) or recommended Phase 2 dose will be determined.

Global Human Papillomavirus Infections Epidemiology and Patient Flow Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 7, 2021
Health, Infectious diseases, Cancer, Health, Epidemiology, Infectious causes of cancer, Papillomavirus, Carcinogenesis, Infectious diseases, Papillomaviridae, Human papillomavirus infection, Virus, Infection, Sexually transmitted infection

b'The "Global Human Papillomavirus Infections Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Human Papillomavirus Infections Epidemiology and Patient Flow Analysis - 2021, provides Human Papillomavirus Infections epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Human Papillomavirus Infections Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Human Papillomavirus Infections Epidemiology and Patient Flow Analysis - 2021, provides Human Papillomavirus Infections epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Human Papillomavirus Infections patients, history of the disease at the population level (Human Papillomavirus Infections prevalence, Human Papillomavirus Infections incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nHuman Papillomavirus Infections patient flow: Human Papillomavirus Infections prevalence, diagnosed, and drug-treated patients\nDemographics: Human Papillomavirus Infections patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Human Papillomavirus Infections market sizing, assessing market potential, and developing drug forecast models\nIdentify Human Papillomavirus Infections patients segments through age groups, gender, and disease sub-types\nEvaluate Human Papillomavirus Infections market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210507005368/en/\n'

Health Monitor Wins Top International Creative Awards

Retrieved on: 
Tuesday, May 4, 2021
Infectious causes of cancer, Papillomavirus, Articles, Carcinogenesis, Carcinogens, Human papillomavirus infection, Health, Clinical medicine, Medical specialties

b'MONTVALE, N.J., May 4, 2021 /PRNewswire/ -- Health Monitor Network, a leading provider of integrated marketing solutions that maximize biopharmaceutical/OTC brand growth and improve health outcomes, today announced that they have won a series of top awards in the preeminent Hermes Creative Awards competition.

Key Points: 
  • b'MONTVALE, N.J., May 4, 2021 /PRNewswire/ -- Health Monitor Network, a leading provider of integrated marketing solutions that maximize biopharmaceutical/OTC brand growth and improve health outcomes, today announced that they have won a series of top awards in the preeminent Hermes Creative Awards competition.
  • The company received numerous platinum and gold awards for their groundbreaking work in direct-to-patient marketing at the point of care.
  • Their award-winning digital and print educational materials have impacted millions of patients suffering from conditions such as diabetes, HPV, IBD, severe asthma, heart attack, stroke, and dermatologic conditions.
  • We hope our contentwhich is validated by leading key opinion leaders and medical associationsis making a difference in people\'s everyday lives.

The American Cancer Society Encourages Parents to Reschedule Missed Vaccine Visits for Kids

Retrieved on: 
Monday, May 3, 2021
Cancer, Papillomavirus, Clinical medicine, Medical specialties, Infectious causes of cancer, Cancer vaccines, Vaccines, Vaccination, Human papillomavirus infection, HPV vaccine, Vaccine, Gardasil

Dataindicate that the COVID-19 pandemic is having a negative effect on vaccination rates.

Key Points: 
  • Dataindicate that the COVID-19 pandemic is having a negative effect on vaccination rates.
  • Most infections become undetectable, but some can go on to cause cancer.\nHPV vaccination works best when given between ages 9 and 12.
  • Children and young adults age 13 through 26 who have not been vaccinated, or who haven\'t gotten all their doses, should get the vaccine as soon as possible.
  • HPV vaccination helps protect boys from cancers of the throat, penis, and anus later in life.